At that time no firm details were announced for the group – which has been valued as high as $47 billion.

According to board member Michael Sen – tasked with the responsibility for the Healthineers – the group should have its “own currency” as it moves away from its imaging core more toward “molecular diagnosis” and “patient self-managment,” according to Reuters.

Although no new acquisitions or mergers are officially in its sights at the moment, he said on the call that, “the equity story begins with a highly attractive portfolio, which we already have."

Sen hinted that there were a number of attractive aspects to listing the entity in the U.S. and not Germany.

"Most peer group companies... are listed in the USA," he explained. "One has to ask where will one get the best research and coverage ... and sufficient market-making capacity and liquidity."

That said, listing in the U.S. does have a downside, according to Kaeser, at least.

Siemens had already announced in February the possibility that it would list the Healthineers in the U.S. and not Europe. “We don't have a final view on this yet, but we are looking at it very closely," Kaeser.

But there was a possible change of heart in early March, when Kaeser told Swiss newspaper Finanz and Wirtschaft that “under President Donald Trump” he “will have to think twice” about where to list the health care unit, mentioning Frankfurt and Hong Kong as possibilities.

Back to HCB News

Business Affairs Homepage